We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human|
|Biochemical Assay (BCA)||1 Antibodies|
|Blocking Antibody (Inhibition)||3 Antibodies|
|Blocking Peptide (BP)||8 Antibodies|
|Blocking Reagent (BR)||6 Antibodies|
|Cell-ELISA (cELISA)||1 Antibodies|
|Cellular Assay (CA)||1 Antibodies|
|Dot Blot (DB)||87 Antibodies|
|ELISA (Capture)||2 Antibodies|
|ELISA (Detection)||1 Antibodies|
|Enzyme Immunoassay (EIA)||55 Antibodies|
|Flow Cytometry (FACS)||525 Antibodies|
|Fluorescence Microscopy (FM)||1 Antibodies|
|Functional Studies (Func)||2 Antibodies|
|Immunoassay (IA)||1 Antibodies|
|Immunochromatography (IC)||25 Antibodies|
|Immunocytochemistry (ICC)||72 Antibodies|
|Immunoelectron Microscopy (IEM)||2 Antibodies|
|Immunofluorescence (IF)||184 Antibodies|
|Antigen||Epidermal Growth Factor Receptor (EGFR) Antibodies|
|Epitope||AA 25-645 Alternatives|
|Conjugate||This EGFR antibody is un-conjugated Alternatives|
ELISA (Capture), Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blotting (WB)
|6 references available|
|Supplier||Log in to see|
Product Details anti-EGFR AntibodyTarget Details EGFR Application Details Handling References for anti-EGFR Antibody (ABIN4899925) Images
|Specificity||Detects human EGF R/ErbB1 in ELISAs and Western blots. In sandwich ELISAs, approximately 3 % cross-reactivity with recombinant mouse EGF R is observed and less than 0.1 % cross-reactivity with recombinant human (rh) ErbB2 and rhErbB3 is observed.|
|Sterility||0.2 μm filtered|
|Immunogen||Mouse myeloma cell line NS0-derived recombinant human EGF R/ErbB1, Leu25-Ser645, Accession # CAA25240|
Target Details EGFRProduct Details anti-EGFR Antibody Application Details Handling References for anti-EGFR Antibody (ABIN4899925) Images back to top
|Alternative Name||EGF R/ErbB1 (EGFR Antibody Abstract)|
|Pathways||NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway|
Application DetailsProduct Details anti-EGFR Antibody Target Details EGFR Handling References for anti-EGFR Antibody (ABIN4899925) Images back to top
|Application Notes||Western Blot 1 μg/mL, Flow Cytometry 0.25 μg/10^6 cells, Immunohistochemistry 1-15 μg/mL, Immunoprecipitation 1 μg/mL, CyTOF-ready, ELISA Capture (Matched Antibody Pair) 0.2-0.8 μg/mL|
|Restrictions||For Research Use only|
HandlingProduct Details anti-EGFR Antibody Target Details EGFR Application Details References for anti-EGFR Antibody (ABIN4899925) Images back to top
|Reconstitution||Reconstitute at 0.2 mg/mL in sterile PBS.|
|Buffer||0.2 m filtered solution in PBS with Trehalose.|
|Storage||4 °C/-20 °C/-80 °C|
|Storage Comment||Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 C as supplied. 1 month, 2 to 8 C under sterile conditions after reconstitution. 6 months, -20 to -70 C under sterile conditions after reconstitution.|
|Expiry Date||12 months|
References for anti-EGFR Antibody (ABIN4899925)Product Details anti-EGFR Antibody Target Details EGFR Application Details Handling Images back to top
|Product cited in:||
Burke, Zsengellér, Khankin, Lo, Rajakumar, DuPont, McCurley, Moss, Zhang, Clark, Wang, Seely, Kang, Stillman, Jaffe, Karumanchi: "Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia." in: The Journal of clinical investigation, Vol. 126, Issue 7, pp. 2561-74, 2016 Method employed by authors: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (Sample species: Human).
Nanjo, Yamada, Nishihara, Takeuchi, Sano, Nakagawa, Ishikawa, Zhao, Ebi, Yasumoto, Matsumoto, Yano: "Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors." in: PLoS ONE, Vol. 8, Issue 12, pp. e84700, 2014 Method employed by authors: Western Blotting (WB) (Sample species: Human).
Sarup, Jin, Turin, Bai, Beryt, Brdlik, Higaki, Jorgensen, Lau, Lindley, Liu, Ni, Rozzelle, Kumari, Watson, Zhang, Shepard: "Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts." in: Molecular cancer therapeutics, Vol. 7, Issue 10, pp. 3223-36, 2008 Method employed by authors: ELISA (ELISA) (Sample species: Human).
Gonzalez, Seurynck-Servoss, Crowley, Brown, Omenn, Hayes, Zangar: "Development and validation of sandwich ELISA microarrays with minimal assay interference." in: Journal of proteome research, Vol. 7, Issue 6, pp. 2406-14, 2008 (Sample species: Human).
Kunii, Davis, Gorenstein, Hatch, Yashiro, Di Bacco, Elbi, Lutterbach: "FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival." in: Cancer research, Vol. 68, Issue 7, pp. 2340-8, 2008 Method employed by authors: Immunoprecipitation (IP) (Sample species: Human).
Murphy, Ghosh, Fulford, Khwaja, Halka, Carter, Turner, Walker: "Expression of growth factors and growth factor receptor in non-healing and healing ischaemic ulceration." in: European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, Vol. 31, Issue 5, pp. 516-22, 2006 Method employed by authors: Immunohistochemistry (IHC) (Sample species: Human).